Sengenics - About the company
Sengenics is an acquired company based in Singapore (Singapore), founded in 2008 by Johan Poole-Johnson. It operates as a Diagnostics and Research using next-generation sequencing, protein and DNA microarray technologies. Sengenics has raised an undisclosed amount in funding. The company has 84 active competitors, including 16 funded and 18 that have exited. Its top competitors include companies like PathogenDX, Agendia and Inflammatix.
Company Details
Sengenics is a genomics and proteomics based diagnostics and research company. Sengenics' flagship product is their patented Immunome autoantibody profiling protein array for use in immunology or cancer research. The Immunome platform was jointly developed by Cambridge and Oxford Universities and is the only protein array platform where all proteins are correctly folded. Apart from their proteomics product, the company offers genomics-based diagnostics services from its CLIA and CAP certified labs using NGS and microarray technologies. The company offers postnatal diagnostics, cardiac and cancer risk tests, and developmental delay diagnostics, along with Sequenom's NIPT - MaterniT21 and VisibiliT tests. The NIPT tests are carried out at Sequenom's CLIA and CAP accredited laboratory. Along with their clinical tests, the company also offers research services to clients in biomarker discovery, NGS, and Bioinformatics.
- Website
- sengenics.com
- Social
- Email ID
- *****@sengenics.com
- Registered Address
- WOODLANDS INDUSTRIAL PARK E1, Singapore, 757716
Key Metrics
Founded Year
2008
Location
Singapore, Singapore
Stage
Acquired
Latest Funding Round
Investors
Ranked
24th among 84 active competitors
Employee Count
50 - 199 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by Summa Equity (Oct 14, 2020)
Legal entities associated with Sengenics
Sengenics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Sonic UK Bidco Limited CIN: 12845227 , United Kingdom, Active | Aug 27, 2020 | - | 3 (As on Dec 31, 2022) | |
SENGENICS CORPORATION PTE. LTD. UEN: 201734100D , Singapore, Active | Nov 27, 2017 | - | - |
Sengenics's acquisition details
Sengenics got acquired by Summa Equity on Oct 14, 2020.
Click here to take a look at Sengenics's acquisition in detail
Sign up to download Sengenics' company profile
Sengenics's funding and investors
Sengenics has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Dec 15, 2020 for $*****. 1 investor participated in its latest round. Sengenics has 3 institutional investors.
Here is the list of recent funding rounds of Sengenics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 15, 2020 | 7315035 | Grant (prize money) | 5718268 | 3463982 | 3934465 | 7440829 |
Access funding benchmarks and valuations. Sign up today!View details of Sengenics's funding rounds and investors
Sengenics' founders and board of directors
Founder? Claim ProfileThe founders of Sengenics is Johan Poole-Johnson. Jerry Williamson is the CEO of Sengenics.
Here are the details of Sengenics' key team members:
- Johan Poole-Johnson: Co-Founder and Chief Commercial Officer of Sengenics.
View details of Sengenics's Founder profiles and Board Members
Sengenics' employee count trend
Sengenics has 50 - 199 employees as of Mar 26. Here is Sengenics's employee count trend over the years:
Uncover Sengenics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sengenics's Competitors and alternates
Top competitors of Sengenics include PathogenDX, Agendia and Inflammatix. Here is the list of Top 10 competitors of Sengenics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | PathogenDX 2014, Tucson (United States), Series B | Provider of DNA-based pathogen testing kits | $11.6M | 62/100 | |
2nd |  Agendia 2003, Irvine (United States), Series F | Provider of genomic diagnostic products for the treatment of cancer | $123M | 61/100 | |
3rd | Inflammatix 2016, San Francisco (United States), Series E | Provider of diagnostic solutions for systemic infections | $191M | 60/100 | |
4th | InDevR 2003, Boulder (United States), Acquired | Manufacturer of biotherapeutics, vaccines and diagnostic products | $16M | 54/100 | |
5th | KromaTiD 2007, Fort Collins (United States), Series C | Provider of molecular and genetic tests for detection of disease-causing mutations | $15.4M | 52/100 | |
6th | GenomeDx Biosciences 2008, San Diego (United States), Series C | Genomic tests for urologic cancers | $69.7M | 50/100 | |
7th | Geneticure 2012, Minnetonka (United States), Series A | Personalized hypertension treatment through DNA analysis for better medication selection | $2.12M | 46/100 | |
8th | Akonni 2003, Frederick (United States), Series C | Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification | $39.7M | 46/100 | |
9th |  Affymetrix 1991, Santa Clara (United States), Acquired | Life science solutions provider: reagents, instruments, and services for scientific discovery | - | 46/100 | |
10th | PamGene 1999, Virginia (United States), Series B | Provider of a microarray platform and gene expression profiling system for post-genomic applications | $17.9M | 43/100 | |
24th | Diagnostics and Research using next-generation sequencing, protein and DNA microarray technologies | - | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Sengenics's competitors? Click here to see the top ones
Sengenics's Investments and acquisitions
Sengenics has made no investments or acquisitions yet.
News related to Sengenics
Filter this list•
Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision MedicineCNW•Jul 30, 2024•Sengenics
•
Sengenics Corporation Announces New Collaboration to Advance Cancer TreatmentPR Newswire•Jun 03, 2024•Sengenics
•
Sengenics Corporation Announces Key Distributor in ChinaPR Newswire•Feb 27, 2024•Youningwei, Sengenics
•
Sengenics Corporation Launches i-Ome Discovery™ to Advance Immune Biomarker Discovery and DevelopmentBusiness Wire•Oct 02, 2023•Sengenics
•
Sengenics Corporation Announces Fredrik Sundberg as New Vice President of Market and Business DevelopmentBusiness Wire•Mar 14, 2023•Sengenics
•
Sengenics Corporation Announces Yvonne Linney, PhD as New Board DirectorBusiness Wire•Jan 09, 2023•Sengenics, Artificial Intelligence, Strateos
•
Sengenics Broadens Its Systems Serology Tools to Enable the Detection of a Wider Range of Autoantibody BiomarkersBusiness Wire•Nov 30, 2022•Sengenics
•
Sengenics Prepares for Next Phase Growth and Welcomes Bioscience Industry Leader as New CEOBusiness Wire•Sep 07, 2022•Sengenics, NanoView Biosciences
•
Sengenics Expands Autoantibody Biomarker Discovery Capability with the Launch of a New Protein Array ServiceBusiness Wire•Mar 22, 2022•Sengenics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Sengenics
Explore our recently published companies
- Inovant Solutions - India based, 2011 founded, Unfunded company
- Infinity StoneX - Visakhapatnam based, Unfunded company
- Southwest Custom Build - Albuquerque based, 2008 founded, Unfunded company
- Grow&Bless Digital - Jakarta based, 2020 founded, Unfunded company
- Eshwar Venugopal - 2013 founded, Unfunded company
- KIWI Agency - Miami based, 2017 founded, Unfunded company
